{"id":38447,"date":"2024-12-18T10:31:49","date_gmt":"2024-12-18T10:31:49","guid":{"rendered":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/"},"modified":"2024-12-18T10:31:49","modified_gmt":"2024-12-18T10:31:49","slug":"un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil","status":"publish","type":"post","link":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/","title":{"rendered":"Un projecte europeu liderat pel Cl\u00ednic-IDIBAPS estudia per primera vegada l\u2019efic\u00e0cia de la immunoter\u00e0pia pel melanoma infantil"},"content":{"rendered":"<p>El treball, emmarcat dins el projecte MELCAYA, demostra que la ter\u00e0pia amb anticossos anti-PD-1 \u00e9s segura en nens i adolescents. I, tot i que \u00e9s efectiva per a pacients que pr\u00e8viament se\u2019ls hi ha extirpat el tumor, no ho \u00e9s tant en els casos m\u00e9s avan\u00e7ats en els que ja hi ha met\u00e0stasi en altres \u00f2rgans.&amp;nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>El treball, emmarcat dins el projecte MELCAYA, demostra que la ter\u00e0pia amb anticossos anti-PD-1 \u00e9s segura en nens i adolescents. I, tot i que \u00e9s efectiva per a pacients que pr\u00e8viament se\u2019ls hi ha extirpat el tumor, no ho \u00e9s tant en els casos m\u00e9s avan\u00e7ats en els que ja hi ha met\u00e0stasi en altres<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"tipo":[],"class_list":["post-38447","post","type-post","status-publish","format-standard","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Un projecte europeu liderat pel Cl\u00ednic-IDIBAPS estudia per primera vegada l\u2019efic\u00e0cia de la immunoter\u00e0pia pel melanoma infantil - Recerca en salut<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un projecte europeu liderat pel Cl\u00ednic-IDIBAPS estudia per primera vegada l\u2019efic\u00e0cia de la immunoter\u00e0pia pel melanoma infantil - Recerca en salut\" \/>\n<meta property=\"og:description\" content=\"El treball, emmarcat dins el projecte MELCAYA, demostra que la ter\u00e0pia amb anticossos anti-PD-1 \u00e9s segura en nens i adolescents. I, tot i que \u00e9s efectiva per a pacients que pr\u00e8viament se\u2019ls hi ha extirpat el tumor, no ho \u00e9s tant en els casos m\u00e9s avan\u00e7ats en els que ja hi ha met\u00e0stasi en altres\" \/>\n<meta property=\"og:url\" content=\"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/\" \/>\n<meta property=\"og:site_name\" content=\"Recerca en salut\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-18T10:31:49+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/12\\\/18\\\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/12\\\/18\\\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Un projecte europeu liderat pel Cl\u00ednic-IDIBAPS estudia per primera vegada l\u2019efic\u00e0cia de la immunoter\u00e0pia pel melanoma infantil\",\"datePublished\":\"2024-12-18T10:31:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/12\\\/18\\\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\\\/\"},\"wordCount\":85,\"commentCount\":0,\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/12\\\/18\\\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/12\\\/18\\\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\\\/\",\"url\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/12\\\/18\\\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\\\/\",\"name\":\"Un projecte europeu liderat pel Cl\u00ednic-IDIBAPS estudia per primera vegada l\u2019efic\u00e0cia de la immunoter\u00e0pia pel melanoma infantil - Recerca en salut\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/#website\"},\"datePublished\":\"2024-12-18T10:31:49+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/12\\\/18\\\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/12\\\/18\\\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/blog\\\/2024\\\/12\\\/18\\\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un projecte europeu liderat pel Cl\u00ednic-IDIBAPS estudia per primera vegada l\u2019efic\u00e0cia de la immunoter\u00e0pia pel melanoma infantil\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/#website\",\"url\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/\",\"name\":\"Recerca en salut\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/diarisanitat.cat\\\/recerca-en-salut\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Un projecte europeu liderat pel Cl\u00ednic-IDIBAPS estudia per primera vegada l\u2019efic\u00e0cia de la immunoter\u00e0pia pel melanoma infantil - Recerca en salut","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/","og_locale":"es_ES","og_type":"article","og_title":"Un projecte europeu liderat pel Cl\u00ednic-IDIBAPS estudia per primera vegada l\u2019efic\u00e0cia de la immunoter\u00e0pia pel melanoma infantil - Recerca en salut","og_description":"El treball, emmarcat dins el projecte MELCAYA, demostra que la ter\u00e0pia amb anticossos anti-PD-1 \u00e9s segura en nens i adolescents. I, tot i que \u00e9s efectiva per a pacients que pr\u00e8viament se\u2019ls hi ha extirpat el tumor, no ho \u00e9s tant en els casos m\u00e9s avan\u00e7ats en els que ja hi ha met\u00e0stasi en altres","og_url":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/","og_site_name":"Recerca en salut","article_published_time":"2024-12-18T10:31:49+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/#article","isPartOf":{"@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/"},"author":{"name":"","@id":""},"headline":"Un projecte europeu liderat pel Cl\u00ednic-IDIBAPS estudia per primera vegada l\u2019efic\u00e0cia de la immunoter\u00e0pia pel melanoma infantil","datePublished":"2024-12-18T10:31:49+00:00","mainEntityOfPage":{"@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/"},"wordCount":85,"commentCount":0,"articleSection":["Uncategorized"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/","url":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/","name":"Un projecte europeu liderat pel Cl\u00ednic-IDIBAPS estudia per primera vegada l\u2019efic\u00e0cia de la immunoter\u00e0pia pel melanoma infantil - Recerca en salut","isPartOf":{"@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/#website"},"datePublished":"2024-12-18T10:31:49+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/blog\/2024\/12\/18\/un-projecte-europeu-liderat-pel-clinic-idibaps-estudia-per-primera-vegada-leficacia-de-la-immunoterapia-pel-melanoma-infantil\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/diarisanitat.cat\/recerca-en-salut\/"},{"@type":"ListItem","position":2,"name":"Un projecte europeu liderat pel Cl\u00ednic-IDIBAPS estudia per primera vegada l\u2019efic\u00e0cia de la immunoter\u00e0pia pel melanoma infantil"}]},{"@type":"WebSite","@id":"https:\/\/diarisanitat.cat\/recerca-en-salut\/#website","url":"https:\/\/diarisanitat.cat\/recerca-en-salut\/","name":"Recerca en salut","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/diarisanitat.cat\/recerca-en-salut\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/posts\/38447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/comments?post=38447"}],"version-history":[{"count":0,"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/posts\/38447\/revisions"}],"wp:attachment":[{"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/media?parent=38447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/categories?post=38447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/tags?post=38447"},{"taxonomy":"tipo","embeddable":true,"href":"https:\/\/diarisanitat.cat\/recerca-en-salut\/wp-json\/wp\/v2\/tipo?post=38447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}